![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Adoptive cell therapy for malignant diseases is showing promise in recent early-phase trials in the treatment of B cell leukemia/lymphoma. Genetically engineered with a tumor-specific chimeric antigen receptor, patient’s T cells produce lasting and complete leukemia regression. However, treatment is associated with some toxicity which needs our attention and the field still faces some hurdles at the scientific, technologic and clinical levels. Surmounting these obstacles will establish chimeric antigen receptor T cell therapy as a powerful approach to cure hematologic malignancies, paving the way for the treatment of other common types of cancer in the future.
Financial & competing interest disclosure
Work in the author’s laboratory is supported by the Deutsche Krebshilfe, the Deutsche Forschungsgemeinschaft, the José Carreras-Leukämie Stiftung, the Wilhelm Sander-Stiftung, the Else Kröner-Fresenius Stiftung, the European Union (European Regional Development Fund – Investing in Your Future), German federal state North Rhine-Westphalia (NRW) and the Medical Faculty of the University. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.